Decreased Bone Type I Collagen in the Early Stages of Chronic Obstructive Pulmonary Disease (COPD)

Carregando...
Imagem de Miniatura
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS INC
Citação
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, v.17, n.5, p.575-586, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) and is known to have deleterious effects on bone metabolism. However, the effects on bone collagen matrix during the development of COPD are unclear. The aim of this study was to evaluate the temporal effect of cigarette smoke exposure on bone type I collagen during COPD development in a cigarette smoke-induced model. C57BL/6 mice were allocated to three groups: control (C), animals exposed to filtered air for 1, 3 and 6 months; cigarette smoke (S), animals exposed to cigarette smoke for 1, 3 and 6 months; provisional smoking (PS), animals exposed to cigarette smoke for 3 months, followed by another 3 months of filtered air exposure. Evaluation of the respiratory mechanics and alveolar enlargement were performed. Femoral and tibial extraction was also performed to evaluate the type I collagen by immunofluorescence andCOL1A1gene expression. Exposure to cigarette smoke led to an alveolar enlargement and progressive reduction in lung tissue resistance and elastance, progressive reduction of type I collagen and reduction inCOL1A1gene expression. Although we did not observe any improvement in the functional and histological parameters in the provisional smoking group, we detected an increase inCOL1A1gene expression. A worsening in bone collagen matrix is part of the initial physiopathological events during COPD development and the smoking cessation induced an evident recovery ofCOL1A1expression, possibly to attempt at tissue repair.
Palavras-chave
Smoking, COPD, bone remodeling, bone matrix, collagen
Referências
  1. Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
  2. Anciaes AM, 2011, CLINICS, V66, P1797, DOI 10.1590/S1807-59322011001000020
  3. [Anonymous], 2019, GLOBAL STRATEGY DIAG
  4. Barbosa AP, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117132
  5. Breitling LP, 2013, ARTERIOSCL THROM VAS, V33, P1468, DOI 10.1161/ATVBAHA.112.300157
  6. BROWN LAS, 1994, AM J PHYSIOL, V266, pL172
  7. Carlson BB, 2016, ORTHOPEDICS, V39, pE318, DOI 10.3928/01477447-20160301-03
  8. Chen F, 2001, Am J Orthop (Belle Mead NJ), V30, P486
  9. Committee for the Update of the Guide for the Care and Use of Laboratory Animals Institute for Laboratory Animal Research Division on Earth and Life Studies & National Research Council, 2011, GUIDE CARE USE LAB A
  10. Cotgreave I A, 1997, Adv Pharmacol, V38, P205
  11. DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298
  12. De Cunto G, 2018, AM J PATHOL, V188, P2195, DOI 10.1016/j.ajpath.2018.06.010
  13. De Cunto G, 2016, AM J PATHOL, V186, P1814, DOI 10.1016/j.ajpath.2016.03.002
  14. DEVERNEJOUL MC, 1983, CLIN ORTHOP RELAT R, P107
  15. Diniz-Fernandes T, 2018, HISTOL HISTOPATHOL, V33, P929, DOI 10.14670/HH-11-982
  16. Exposito JY, 2010, INT J MOL SCI, V11, P407, DOI 10.3390/ijms11020407
  17. Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3
  18. FANG MA, 1991, BONE, V12, P283, DOI 10.1016/8756-3282(91)90077-V
  19. FENG G, 2009, J EYE MOVEMENT RES, V3, DOI 10.2174/187231309788166398
  20. Forey BA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-36
  21. Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
  22. Gomes RFM, 2000, J APPL PHYSIOL, V89, P908
  23. HANTOS Z, 1992, J APPL PHYSIOL, V72, P168
  24. Hecht SS, 2006, LANGENBECK ARCH SURG, V391, P603, DOI 10.1007/s00423-006-0111-z
  25. Henemyre CL, 2003, J PERIODONTOL, V74, P1440, DOI 10.1902/jop.2003.74.10.1440
  26. Hernigou J, 2019, BONE JOINT RES, V8, P255, DOI 10.1302/2046-3758.86.BJR-2018-0344.R1
  27. Hernigou J, 2013, INT ORTHOP, V37, P883, DOI 10.1007/s00264-013-1809-5
  28. Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST
  29. Inoue D, 2016, INT J CHRONIC OBSTR, V11, P637, DOI 10.2147/COPD.S79638
  30. International Agency for Research on Cancer. World Health Organization, 2007, IARC HDB CANC PREV
  31. Ito JT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209351
  32. Kamer AR, 2006, INT J MOL MED, V17, P121
  33. Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI [10.1007/s00198-004-1734-y, 10.1007/s00198-004-1640-3]
  34. LENZ LG, 1992, P SOC EXP BIOL MED, V199, P211
  35. Little CP, 2006, J HAND SURG-BRIT EUR, V31B, P252, DOI 10.1016/j.jhsb.2005.12.010
  36. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  37. Llinas L, 2011, PULM PHARMACOL THER, V24, P32, DOI 10.1016/j.pupt.2010.10.010
  38. Lopes FDTQS, 2013, HISTOL HISTOPATHOL, V28, P269, DOI 10.14670/HH-28.269
  39. Oncken C, 2006, J WOMENS HEALTH, V15, P1141, DOI 10.1089/jwh.2006.15.1141
  40. RAMP WK, 1991, P SOC EXP BIOL MED, V197, P36
  41. Rothem DE, 2009, J BONE MINER METAB, V27, P555, DOI 10.1007/s00774-009-0075-5
  42. Sasaki M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191611
  43. Szulc P, 2002, J CLIN ENDOCR METAB, V87, P666, DOI 10.1210/jc.87.2.666
  44. Takubo Y, 2002, AM J RESP CRIT CARE, V166, P1596, DOI 10.1164/rccm.2202001
  45. Talhout R, 2011, INT J ENV RES PUB HE, V8, P613, DOI 10.3390/ijerph8020613
  46. Teodoro WR, 2004, PATHOL RES PRACT, V200, P681, DOI 10.1016/j.prp.2004.05.007
  47. Theiss SM, 2000, SPINE, V25, P2588, DOI 10.1097/00007632-200010150-00008
  48. Toledo AC, 2012, EUR RESPIR J, V39, P254, DOI 10.1183/09031936.00003411
  49. Toumpanakis D, 2010, AM J RESP CRIT CARE, V182, P1129, DOI 10.1164/rccm.201001-0116OC
  50. Tsukamoto M, 2019, BONE, V120, P114, DOI 10.1016/j.bone.2018.10.017
  51. Vrieze A, 2007, OSTEOPOROSIS INT, V18, P1197, DOI 10.1007/s00198-007-0355-7
  52. WAGNER PD, 1989, EUR RESPIR J, V2, P116
  53. Wang XM, 2014, CELL BIOCHEM BIOPHYS, V70, P129, DOI 10.1007/s12013-014-9868-9
  54. World Health Organization, 2013, ENF BANS TOB ADV PRO